Vaccinex Inc. [NASDAQ: VCNX] traded at a high on 11/10/20, posting a 26.37 gain after which it closed the day’ session at $2.30. The company report on October 29, 2020 that CORRECTION — Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference.
SIGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease.
Data provide strong rationale for continued development in Huntington’s and other slowly progressive neurodegenerative diseases, including Alzheimer’s.
The results of the trading session contributed to over 12295605 shares changing hands. Over the past one week, the price volatility of Vaccinex Inc. stands at 21.91% while the volatility over the past one month is 10.83%.
The market cap for VCNX stock reached $47.06 million, with 16.69 million shares outstanding and 15.90 million shares in the current float. Compared to the average trading volume of 896.78K shares, VCNX reached a trading volume of 12295605 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Vaccinex Inc. [VCNX]?
BTIG Research have made an estimate for Vaccinex Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 23, 2020. While these analysts kept the previous recommendation, Ladenburg Thalmann raised their target price to Buy. The new note on the price target was released on September 04, 2018, representing the official price target for Vaccinex Inc. stock.
The Average True Range (ATR) for Vaccinex Inc. is set at 0.23, with the Price to Sales ratio for VCNX stock in the period of the last 12 months amounting to 117.64.
How has VCNX stock performed recently?
Vaccinex Inc. [VCNX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 30.68. With this latest performance, VCNX shares gained by 10.05% in over the last four-week period, additionally sinking by -36.99% over the last 6 months – not to mention a drop of -57.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VCNX stock in for the last two-week period is set at 50.00, with the RSI for the last a single of trading hit 69.63, and the three-weeks RSI is set at 47.59 for Vaccinex Inc. [VCNX]. The present Moving Average for the last 50 days of trading for this stock 2.83, while it was recorded at 1.90 for the last single week of trading, and 4.29 for the last 200 days.
Vaccinex Inc. [VCNX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Vaccinex Inc. [VCNX] shares currently have an operating margin of -6121.41 and a Gross Margin at +14.34. Vaccinex Inc.’s Net Margin is presently recorded at -6092.35.
Reflecting on the efficiency of the workforce at the company, Vaccinex Inc. [VCNX] managed to generate an average of -$650,265 per employee. Receivables Turnover for the company is 0.68 with a Total Asset Turnover recorded at a value of 0.04.Vaccinex Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.30 and a Current Ratio set at 0.30.
Earnings analysis for Vaccinex Inc. [VCNX]
With the latest financial reports released by the company, Vaccinex Inc. posted -0.56/share EPS, while the average EPS was predicted by analysts to be reported at -0.66/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 15.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VCNX.
Insider trade positions for Vaccinex Inc. [VCNX]
There are presently around $3 million, or 60.20% of VCNX stock, in the hands of institutional investors. The top three institutional holders of VCNX stocks are: MSD PARTNERS, L.P. with ownership of 922,546, which is approximately -20.597% of the company’s market cap and around 2.50% of the total institutional ownership; VANGUARD GROUP INC, holding 138,297 shares of the stock with an approximate value of $0.32 million in VCNX stocks shares; and OPPENHEIMER & CO INC, currently with $81000.0 in VCNX stock with ownership of nearly 27.847% of the company’s market capitalization.
Positions in Vaccinex Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 12 institutional holders increased their position in Vaccinex Inc. [NASDAQ:VCNX] by around 64,589 shares. Additionally, 5 investors decreased positions by around 253,675 shares, while 2 investors held positions by with 916,110 shares. The mentioned changes placed institutional holdings at 1,234,374 shares, according to the latest SEC report filing. VCNX stock had 6 new institutional investments in for a total of 50,099 shares, while 0 institutional investors sold positions of 0 shares during the same period.